Martin Milita served as the Medicaid inspector general for the state of New Jersey for five years. In this role, Martin Milita provided a crucial service, as all states are legally obligated to operate a Medicaid Fraud Control Unit (MFCU) or provide proof of active fraud protection alternatives.
Recent trends show that MFCUs are quite necessary, especially in the areas of pharmaceutical manufacturing and distribution. According to the U.S. Department of Health and Human Services, in 2013, 62 percent of civil settlements and judgments carried out by MFCUs involved prescription drug manufacturing. Additionally, the largest MFCU monetary criminal recovery to date occurred in 2013. This record-setting recovery resulted from a manufacturer’s admission to unlawfully and falsely promoting a prescription drug for unapproved uses.
The investigated manufacturer also faced allegations of illegal marketing; false information regarding safety, efficacy, and dosing; and illegal payment given to health care professionals and pharmacies. Although pharmaceutical companies are usually not enrolled Medicaid suppliers, illegal activities are often targeted toward marketing specific prescription medications to Medicaid suppliers and beneficiaries, thus falling under the domain of Medicaid Fraud Control Units.